Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 4/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 3/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508270 | 0.88 | MAP3K11 (0.42) | KITTNIKPDPK1CYP3A4MAP3K11 | |
| SCHEMBL16508295 | 0.86 | CYP3A4 (0.49) | FYNTNIKCYP3A4 | |
| SCHEMBL16508297 | 0.85 | CYP3A4 (0.35) | CYP3A4MAPT | |
| SCHEMBL16508296 | 0.81 | PDE1A (0.38) | CYP3A4MAPT | |
| SCHEMBL12302501 | 0.74 | CYP3A4 (0.39) | KITRIOK2CYP3A4MAP3K11 | |
| SCHEMBL1702845 | 0.74 | CYP3A4 (0.39) | AXLAAK1CYP3A4 | |
| SCHEMBL2447905 | 0.73 | MAP3K11 (0.41) | KITTNIKPDPK1CYP3A4MAP3K11 | |
| SCHEMBL1702611 | 0.73 | CYP3A4 (0.39) | KITAXLAAK1RIPK1CYP3A4 | |
| SCHEMBL16508298 | 0.73 | JAK2 (0.34) | CYP3A4MAPT | |
| SCHEMBL1702764 | 0.72 | CYP3A4 (0.57) | FYNCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | SGK1 4511/4885CAMKK2 4667/4885KIT 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.